Johnson & Johnson vs Micron Technology, Inc. — how do they compare? Johnson & Johnson trades at $249.4 (market cap $598.96B), while Micron Technology, Inc. trades at $970.2 (market cap $977.44B). The key difference: Micron Technology, Inc. is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | MU | |
|---|---|---|
Market Cap | $598.96B | $977.44B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $1.21K |
52-Week Low | $164.36 | $104.88 |
Enterprise Value | $631.90B | $957.80B |
Dividend Yield | 2.15% | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Micron (MU) trades at $862.32, down 1.57% with a bearish technical signal, though it remains 30% below its 52-week high. The company reported strong Q3 2025 earnings of $4.78 EPS, beating expectations, with revenue surging to $37.38 billion. Analyst consensus is strongly bullish with an 81.43% buy rating and a $1,550 price target. Recent news highlights memory chip demand driven by AI, though sector-wide bear market concerns persist.
Outlook remains positive due to robust AI-driven memory demand and earnings beats, but risks include cyclical industry volatility and competitive pressures. The stock offers growth potential if it maintains execution amid high expectations, yet investors should monitor sector sentiment and guidance updates for sustainability.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →